Mizuho Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

Enliven Therapeutics (NASDAQ:ELVN) had its price target boosted by equities researchers at Mizuho from $41.00 to $45.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s target price indicates a potential upside of 26.99% from the stock’s current price.

Several other research firms have also issued reports on ELVN. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.80.

Enliven Therapeutics Stock Up 13.8%

ELVN traded up $4.29 during trading on Wednesday, hitting $35.44. The company’s stock had a trading volume of 2,852,680 shares, compared to its average volume of 1,180,769. The business’s 50 day simple moving average is $27.85 and its 200-day simple moving average is $22.63. The firm has a market cap of $2.12 billion, a PE ratio of -19.04 and a beta of 0.33. Enliven Therapeutics has a one year low of $13.30 and a one year high of $36.72.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). Equities research analysts expect that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Anish Patel sold 48,300 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the sale, the chief operating officer owned 215,011 shares in the company, valued at approximately $6,018,157.89. This trade represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard A. Heyman sold 9,635 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $25.03, for a total value of $241,164.05. Following the sale, the director directly owned 25,545 shares in the company, valued at $639,391.35. This trade represents a 27.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 232,180 shares of company stock worth $6,217,033. 25.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth about $83,000. Quantbot Technologies LP boosted its stake in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Enliven Therapeutics during the 4th quarter valued at approximately $95,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.